GR1000558B - Μεθοδος παρασκευης οφθαλμικης συνθεσεως κυκλοσπορινης. - Google Patents
Μεθοδος παρασκευης οφθαλμικης συνθεσεως κυκλοσπορινης.Info
- Publication number
- GR1000558B GR1000558B GR880100578A GR880100578A GR1000558B GR 1000558 B GR1000558 B GR 1000558B GR 880100578 A GR880100578 A GR 880100578A GR 880100578 A GR880100578 A GR 880100578A GR 1000558 B GR1000558 B GR 1000558B
- Authority
- GR
- Greece
- Prior art keywords
- cyclosporine
- composition
- enhance
- corn oil
- ophthalmological
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 4
- 108010036949 Cyclosporine Proteins 0.000 title abstract 4
- 229960001265 ciclosporin Drugs 0.000 title abstract 4
- 229930182912 cyclosporin Natural products 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title 1
- 239000002285 corn oil Substances 0.000 abstract 2
- 235000005687 corn oil Nutrition 0.000 abstract 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 229940087168 alpha tocopherol Drugs 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- -1 antifungals Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 abstract 1
- 229960003870 bromhexine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960002216 methylparaben Drugs 0.000 abstract 1
- 229940066491 mucolytics Drugs 0.000 abstract 1
- 229960001416 pilocarpine Drugs 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 230000004489 tear production Effects 0.000 abstract 1
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000005526 vasoconstrictor agent Substances 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
- 235000004835 α-tocopherol Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Μέθοδος για αύξηση ή επανόρθωση διακρυικής λειτουργίας με την τοπική χορήγηση κυκλοσπορίνης σε φαρμακευτικώς αποδεκτό έκδοχο. Η διακρυική λειτουργία αυξάνεται ή επανορθώνεται σε ασθενείς που υποφέρουν από ανωμαλίες του δακρυικού φιλμ, που συμπεριλαμβάνει απόλυτη ή μερική ανεπάρκεια σε παραγωγή υδατικών δακρύων, καλούμενη ξηρά κερατοεπιπεφυκίτιδα ή KCS, ανεξαρτήτως αιτιολογίας, συμπεριλαμβανομένης της αυτοανοσο δυσλειτουργίας των δακρυικών αδένων. Η θεραπεία είναι επίσης χρήσιμη στην αύξηση ή την επανόρθωση κανονικής παραγωγής δακρύων και κανονική επούλωση της επιφάνειας του οφθαλμού. Η προτιμώμενη σύνθεση για τοπική χορήγηση του οφθαλμού, συνίσταται από κυκλοσπορίνη διαλελυμένη σε αραβοσιτέλαιο. Η σύνθεση μπορεί περαιτέρω να περιλαμβάνει αντιοξειδωτικά, λιπαντικά, αντιβιοτικά, αντιμυκητικά, αντιιοσικά, αντιφλεγμονώδη (δηλαδή κορτικοστεροειδή), πιλοκαρπίνη, αγγειοσυσταλτικά, επιφανειοδραστικά, υγραντικούς παράγοντες, συντηρρητικά, βλεννολυτικούς παράγοντες (δηλαδή βρωμεξίν, ακετολοκυστείνη), καθώς επίσης άλλες ενώσεις. Η πλέον προτιμώμενη σύνθεση είναι 2% κυκλοσπορίνη, 1 μόριο % άλφα τοκοφερόλη και 0.005% μεθυλ παραμπέν σε αραβοσιτέλαιο. ω
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/092,466 US4839342A (en) | 1987-09-03 | 1987-09-03 | Method of increasing tear production by topical administration of cyclosporin |
| US11721887A | 1987-11-04 | 1987-11-04 | |
| US18782388A | 1988-04-29 | 1988-04-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GR880100578A GR880100578A (en) | 1989-06-22 |
| GR1000558B true GR1000558B (el) | 1992-08-26 |
Family
ID=27377210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR880100578A GR1000558B (el) | 1987-09-03 | 1988-09-05 | Μεθοδος παρασκευης οφθαλμικης συνθεσεως κυκλοσπορινης. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5411952A (el) |
| EP (1) | EP0391909B1 (el) |
| JP (1) | JPH0667850B2 (el) |
| KR (1) | KR920003601B1 (el) |
| AT (1) | ATE109970T1 (el) |
| DE (1) | DE3851152T2 (el) |
| DK (1) | DK54390A (el) |
| ES (1) | ES2012116A6 (el) |
| GR (1) | GR1000558B (el) |
| IE (1) | IE65582B1 (el) |
| PH (1) | PH24814A (el) |
| WO (1) | WO1989001772A1 (el) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| ZA927277B (en) * | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| SG45449A1 (en) | 1992-05-13 | 1998-01-16 | Sandoz Ltd | Ophthalmic compositions |
| US5830508A (en) | 1992-08-06 | 1998-11-03 | Deo Corporation | Composition for treating dry eye |
| US5366739A (en) * | 1992-08-06 | 1994-11-22 | Deo Corporation | Method of ophthalmic drug delivery |
| US5686436A (en) | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
| US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| IE75744B1 (en) * | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| CA2246265A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
| PT880363E (pt) | 1996-02-13 | 2002-12-31 | Searle & Co | Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4 |
| WO1997032585A1 (en) * | 1996-03-05 | 1997-09-12 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| DE69840586D1 (de) | 1997-10-08 | 2009-04-02 | Isotechnika Inc | Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien |
| US6861411B1 (en) | 1997-12-02 | 2005-03-01 | Pfizer, Inc. | Method of treating eye infections with azithromycin |
| US5981607A (en) * | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| GB9818278D0 (en) * | 1998-08-22 | 1998-10-14 | Smith & Nephew | Compositions |
| US20040121014A1 (en) * | 1999-03-22 | 2004-06-24 | Control Delivery Systems, Inc. | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6255280B1 (en) | 1999-04-08 | 2001-07-03 | University Of Kentucky Research Foundation | Protection against traumatic brain injury |
| US6254860B1 (en) * | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| BRPI0014869B8 (pt) * | 1999-10-15 | 2021-05-25 | Sucampo Ag | prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização |
| ATE250924T1 (de) | 2000-04-07 | 2003-10-15 | Medidom Lab | Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel |
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US20030021816A1 (en) * | 2001-06-06 | 2003-01-30 | Sewon Kang | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| DE60231570D1 (de) | 2001-10-19 | 2009-04-23 | Isotechnika Inc | Synthese von Cyclosporinanalogen |
| KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
| US8871241B2 (en) * | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| US6930127B2 (en) * | 2002-08-15 | 2005-08-16 | Eaton Veterinary Laboratories, Inc. | Veterinary treatment of ophthalmic disease in animals using topical tacrolimus |
| US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| AU2004222306A1 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
| EP2359817B1 (en) * | 2003-03-28 | 2018-01-10 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
| US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| CA2553381C (en) | 2004-01-20 | 2011-03-22 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US7923471B2 (en) * | 2004-05-14 | 2011-04-12 | Alcon, Inc. | Method of treating dry eye disorders and uveitis |
| US20050277584A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| EP2153824A1 (en) * | 2004-09-27 | 2010-02-17 | Sigmoid Pharma Limited | Seamless multiparticulate formulations |
| JP2008514702A (ja) * | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006039163A2 (en) * | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
| US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
| WO2006073786A2 (en) * | 2004-12-30 | 2006-07-13 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| CA2615990A1 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
| US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| WO2007047334A1 (en) * | 2005-10-14 | 2007-04-26 | Allergan, Inc. | Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| AU2006311577B2 (en) * | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| US7655625B2 (en) * | 2006-02-13 | 2010-02-02 | Allergan, Inc. | Methods of treating blepharospasm using cyclosporine components |
| US7557082B2 (en) | 2006-03-03 | 2009-07-07 | Allergan, Inc. | Treatment with cyclosporin A |
| US20070219127A1 (en) * | 2006-03-20 | 2007-09-20 | Walt John G | Cyclosporin a compositions |
| US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US20080146497A1 (en) * | 2006-07-25 | 2008-06-19 | Graham Richard S | Cyclosporin Compositions |
| WO2008122965A2 (en) | 2007-04-04 | 2008-10-16 | Sigmoid Pharma Limited | Pharmaceutical cyclosporin compositions |
| BRPI0811538A2 (pt) * | 2007-05-04 | 2015-08-11 | Allergan Inc | Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares. |
| US20090081277A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| AU2008310956B2 (en) | 2007-10-08 | 2014-08-07 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
| ITMI20080003A1 (it) * | 2008-01-02 | 2009-07-03 | Alfredo Pulpito | Composizioni per uso oftalmico |
| CA2729834A1 (en) * | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
| US9445975B2 (en) * | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
| BRPI1006826A2 (pt) | 2009-01-08 | 2017-08-15 | Allergan Inc | Composições para melhorar o crescimento de unhas |
| US20110009339A1 (en) * | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
| ES2530049T3 (es) | 2009-05-18 | 2015-02-26 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| PL2437762T3 (pl) | 2009-06-05 | 2018-01-31 | Allergan Inc | Sztuczne łzy i ich zastosowania terapeutyczne |
| MX338355B (es) * | 2009-06-09 | 2016-04-13 | Aurinia Pharmaceuticals Inc | Sistemas de suministro de farmaco topico para uso oftalmico. |
| EP2464341B1 (en) | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| CA2785468A1 (en) * | 2009-12-23 | 2011-06-30 | Psivida Us, Inc. | Sustained release delivery devices |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| US8957048B2 (en) | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
| RU2639393C2 (ru) | 2011-11-15 | 2017-12-21 | Аллерган, Инк. | Состав пролонгированного действия циклоспорина формы 2 |
| CN104080442B (zh) | 2011-11-15 | 2018-01-05 | 阿勒根公司 | 环孢菌素a形式2的悬浮液 |
| EP2780358B1 (en) | 2011-11-15 | 2016-03-23 | Allergan, Inc. | Cyclosporine a form 2 and method of making same |
| US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
| US20130266615A1 (en) * | 2012-04-10 | 2013-10-10 | Bin Wu | Non-immunogenic delivery vehicle for beta-, gamma-, and delta-tocopherols and methods of using and making same |
| WO2013158296A1 (en) * | 2012-04-20 | 2013-10-24 | Howard University | Method of treating an ocular disease and compositions effective for treating an ocular disease |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| HUE053624T2 (hu) | 2014-11-07 | 2021-07-28 | Sublimity Therapeutics Ltd | Ciklosporint tartalmazó készítmények |
| CA2967413C (en) | 2014-11-25 | 2023-08-15 | Allergan, Inc. | Ophthalmic compositions containing omega-3 oils stabilized by antioxidants |
| US9820954B2 (en) | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| JP7598699B2 (ja) * | 2017-06-01 | 2024-12-12 | ロート製薬株式会社 | 視覚機能の再活性化用眼科組成物 |
| WO2025248489A1 (en) * | 2024-05-29 | 2025-12-04 | Sight Sciences, Inc. | Bio-erodible ocular implants for treatment of conditions of the eye |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3608073A (en) * | 1968-07-16 | 1971-09-21 | Barnes Hind Pharm Inc | Emulsion of pilocarpine for ophthalmic use |
| CH614931A5 (el) * | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
| US4210581A (en) * | 1975-11-04 | 1980-07-01 | Sandoz Ltd. | Organic compounds |
| US4117118A (en) * | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
| US4115544A (en) * | 1976-08-18 | 1978-09-19 | Alza Corporation | Ocular system made of bioerodible esters having linear ether |
| DE2819094A1 (de) * | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
| FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| US4215199A (en) * | 1978-06-05 | 1980-07-29 | Sandoz Ltd. | Antibiotic production |
| SE448386B (sv) * | 1978-10-18 | 1987-02-16 | Sandoz Ag | Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem |
| ATE43335T1 (de) * | 1980-02-14 | 1989-06-15 | Sandoz Ag | Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung. |
| US4396542A (en) * | 1980-02-14 | 1983-08-02 | Sandoz Ltd. | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
| EP0056782B1 (en) * | 1981-01-09 | 1984-08-01 | Sandoz Ag | Novel cyclosporins |
| EP0090798A1 (en) * | 1981-10-09 | 1983-10-12 | Ferring AB | A drug based on a substance p antagonist |
| EP0145714A1 (en) * | 1983-05-25 | 1985-06-26 | Alcon Laboratories, Inc. | Ophthalmic gel |
| US4708861A (en) * | 1984-02-15 | 1987-11-24 | The Liposome Company, Inc. | Liposome-gel compositions |
| CH667274A5 (de) * | 1984-03-23 | 1988-09-30 | Sandoz Ag | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| EP0365044A3 (en) * | 1984-08-02 | 1990-08-22 | Sandoz Ag | Novel pharmaceutical use of (nva)2-cyclosporine |
| GB8422253D0 (en) * | 1984-09-04 | 1984-10-10 | Sandoz Ltd | Organic compounds |
| EP0194972B1 (en) * | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US4649047A (en) * | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
| JPS61249918A (ja) * | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | 点眼剤 |
| US4745100A (en) * | 1985-05-14 | 1988-05-17 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion |
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| GB8528032D0 (en) * | 1985-11-13 | 1985-12-18 | Ici Plc | Ocular treatment |
| US4923699A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Eye treatment suspension |
-
1988
- 1988-08-31 WO PCT/US1988/003039 patent/WO1989001772A1/en not_active Ceased
- 1988-08-31 KR KR1019890700680A patent/KR920003601B1/ko not_active Expired
- 1988-08-31 EP EP88908033A patent/EP0391909B1/en not_active Expired - Lifetime
- 1988-08-31 DE DE3851152T patent/DE3851152T2/de not_active Expired - Lifetime
- 1988-08-31 JP JP63507463A patent/JPH0667850B2/ja not_active Expired - Lifetime
- 1988-08-31 AT AT88908033T patent/ATE109970T1/de not_active IP Right Cessation
- 1988-09-02 IE IE266388A patent/IE65582B1/en not_active IP Right Cessation
- 1988-09-02 ES ES8802718A patent/ES2012116A6/es not_active Expired - Lifetime
- 1988-09-02 PH PH37495A patent/PH24814A/en unknown
- 1988-09-05 GR GR880100578A patent/GR1000558B/el not_active IP Right Cessation
-
1990
- 1990-02-06 US US07/474,683 patent/US5411952A/en not_active Expired - Lifetime
- 1990-03-01 DK DK054390A patent/DK54390A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IE65582B1 (en) | 1995-11-01 |
| WO1989001772A1 (en) | 1989-03-09 |
| GR880100578A (en) | 1989-06-22 |
| DK54390D0 (da) | 1990-03-01 |
| ATE109970T1 (de) | 1994-09-15 |
| IE882663L (en) | 1989-03-03 |
| KR920003601B1 (ko) | 1992-05-04 |
| DK54390A (da) | 1990-05-03 |
| JPH0667850B2 (ja) | 1994-08-31 |
| US5411952A (en) | 1995-05-02 |
| EP0391909A1 (en) | 1990-10-17 |
| EP0391909B1 (en) | 1994-08-17 |
| KR890701084A (ko) | 1989-12-19 |
| DE3851152D1 (de) | 1994-09-22 |
| JPH03503159A (ja) | 1991-07-18 |
| PH24814A (en) | 1990-10-30 |
| DE3851152T2 (de) | 1995-01-26 |
| ES2012116A6 (es) | 1990-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR880100578A (en) | Ophthalmological cyclosporine composition and preparation method | |
| CA1303503C (en) | Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex | |
| AU690377B2 (en) | Application of superoxide dismutase in liposomes | |
| MX9702349A (es) | Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma. | |
| CA2059403A1 (en) | Use of Carrageenans in Topical Ophthalmic Compositions | |
| DK0703774T3 (da) | Stærktskummende oral sammensætning | |
| EP1225168A3 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| IE811654L (en) | Ophthalmic composition | |
| IE831611L (en) | Topical anti-inflammatory compositions | |
| AU3232789A (en) | Anesthetic skin moisturizing composition and method of preparing same | |
| GB2075341B (en) | Pharmaceutical compositions | |
| US4197301A (en) | Topical ophthalmic use of Prazosin | |
| DE3167210D1 (en) | Pharmaceutical composition | |
| KR880007068A (ko) | 13-시스 레티노산의 용도 | |
| EP0345028A3 (en) | Treatment of glaucoma using phosphodiesterase inhibitor | |
| KR950702422A (ko) | (에스)-티몰롤 헤미하이드레이트를 함유하는 안약 국소 조성물(ophthalmic topical composition containing (s)-timolol hemihydrate) | |
| RU95106983A (ru) | Офтальмологический состав, способ его получения и средство для офтальмологического состава | |
| CA2015427A1 (en) | Pharmaceutical composition for topical ophthalmic use having improved local tolerability | |
| KeeS | Johnson Syndrome are two disorders usually described as mucin deficiency dry eye syndromes. A classic example of mucin deficiency caused by degeneration or loss of goblet cells is hypo-vitaminosis A. This can be induced experimentally in laboratory animals and is found endemically in developing countries. It appears that Vitamin A is necessary for maturation of goblet cells, and that it | |
| MY100229A (en) | Topical anti-inflammatory compositions. | |
| EP0456988A3 (en) | Use of naproxen as mydriatic agent | |
| IT1257884B (it) | Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari a base di vincamina o di un suo sale farmaceuticamente accettabile. | |
| CA2243824A1 (en) | Therapeutic agent for keratoconjunctiva diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Right expired |